We build pioneering companies and advance their pipeline to make a positive impact on health and well-being.

Mission

We invest in and build companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. We differentiate ourselves by using our network, expertise and resources to achieve long-term success for our companies. We have the utmost respect for all our stakeholders and strive to be described by them as a great partner.

Flerie's story

Latest Portfolio Company News

November 4, 2024

Neogap Therapeutics partners with NorthX Biologics to advance scalable manufacturing for its novel cancer cell therapy

flerie-subscribe-banner

November 1, 2024

Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million

flerie-subscribe-banner

October 23, 2024

Toleranzia receives approximately SEK 37 million through the warrants of series TO4 which were exercised to approximately 85 percent

flerie-subscribe-banner

See all Portfolio Company News

Latest Press Releases

November 4, 2024 08:00

NET ASSET VALUE – 31 October 2024

October 16, 2024 17:00 Non Regulatory

Flerie AB’s Nomination Committee for the 2025 Annual General Meeting

October 16, 2024 08:00 Regulatory

Interim report January – September 2024

See all Press Releases

Interim report Q3 2024

The interim report for the third quarter 2024 was published on Wednesday October 16 at 08:00 CEST.

Presentation: the same day at 14:00 CEST.

October 16, 2024 Report (eng) Download Report (eng)
October 16, 2024 Rapport (sv) Download Rapport (sv)
Webcast Webcast

Financial Calendar

January 22, 2025

Year-end report 2024
Add to calendar
April 23, 2025

Annual Report 2024
Add to calendar

All events